… and plasma AR gene gain are associated with shorter progression-free (PFS) and overall
survival (OS) with abiraterone or enzalutamide … were also associated with a worse outcome in …

… the ARPIs abiraterone acetate or enzalutamide. Elevated total … -derived DNA at baseline
had worse outcomes on hormonal … association between plasma cfDNA and clinical outcomes …

… DNA (ctDNA) fraction in plasma and androgen receptor (AR) copy number (CN) gain correlates
with worse outcomes… if plasma DNA analysis and AR status associates with PSA kinetics. …

… , particularly AR copy number, in plasma DNA is a minimally … clinical outcome and resistance
to abiraterone/enzalutamide … for the association of AR status with outcome for men at …

… : Plasma androgen receptor (AR) copy number (CN) status … was associated with resistance
to these therapies, both in pre- … This study evaluated 73 patients with sufficient plasma DNA …

… this polymorphism is associated with outcomes for metastatic … adrenal androgens into the
androgen receptor (AR) ligands … , complete blood counts, plasma/serum biochemical panel, …

… -based AR gain is associated with a worse response to ARSIs… Only the results for the
association between outcome and AR … strongly associated with an inferior response to …

… and their impact on the clinical outcome of AR-directed drugs … abiraterone and enzalutamide
and is associated to worse OS … DNA was quantified by a spectrophotometer (Nanodrop ND-…

… copies) had significantly worse outcomes when treated with … -associated genomic changes
converge upon the AR gene … F877L mutation can convert enzalutamide and apalutamide …

… such as abiraterone and enzalutamide. Still, approximately … Can we predict resistance to
androgen receptor (AR)–… (CTCs) and its association with resistance to androgen receptor (AR)–…